Skip to content
Peptigraph home

AOD-9604 and MOTS-c Together: What Is Known

AOD-9604 and MOTS-c taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
HGH fragment analogNot FDA approved · research chemicalAOD-9604Fragment of human growth hormone studied only in animals; in rats, 19 days of oral treatment reduced body-weight gain by over 50%.[5]GLP-1 & metabolicMitochondrial-derived peptidePCAC voted 7–5 for 503A (Jul 2026)MOTS-cMitochondrial-derived peptide; human studies found only measured the body's own circulating levels (for example after repeated heat treatment), not administered MOTS-c.[8]GLP-1 & metabolic
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 1 result, 2 Oct 2026).

Neither is FDA approved for use in people, and we have no sourced data on combining them.
Each component

Side by side

Showing 10 of 12 fields where the two differ. Category, Half-life are the same or both unknown.

FieldAOD-9604MOTS-c
ClassHGH fragment analogMitochondrial-derived peptide
Also calledAODmots
FDA statusNot FDA approved · research chemicalPCAC voted 7–5 for 503A (Jul 2026)
PCAC vote, Jul 2026Not on the Jul 2026 agendaPCAC voted 7–5 for the 503A list (Jul 2026); not finalized
WADAProhibited by WADA (S2.2.3)AOD-9604 is named as a growth hormone fragment in S2.2.3, prohibited at all times.Prohibited by WADA (S4.4.1)MOTS-c is named in S4.4.1 (metabolic modulators: AMPK activators), prohibited at all times.
Anti-doping detection
  • AOD9604 can be detected in urine at 50 pg/mL; a stable serum metabolite may lengthen the detection window.PMID 25208511
  • Screening for a stable metabolite may allow a longer detection window (no duration was given).PMID 25208511
  • A plasma (blood) test for MOTS-c has been validated to WADA standards.PMID 30394592
Evidence strengthAnimal evidence, 2 of 4Strongest: Annals of clinical and laboratory science 2015, PMID 26275694Human RCT evidence, 4 of 4Strongest: Medicine and science in sports and exercise 2025, PMID 40674654
Human studies we summarised0 human (0 randomized or controlled) of 4 summarised7 human (4 randomized or controlled) of 15 summarised
Typical study doses
Vial sizes sold2 mg, 5 mg, 10 mg5 mg, 10 mg, 20 mg, 40 mg
Related tools

AOD-9604 vs MOTS-c

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison

Fat metabolism in mice, two angles

Chronic AOD treatment reduced body weight gain in obese mice, which the authors linked to higher fat oxidation and plasma glycerol.[20]

MOTS-c in mice prevented ovariectomy-induced obesity and insulin resistance.[21]

MOTS-c also attenuated muscle loss in immobilised mice: immobilisation reduced about 15% of muscle mass, but only 5% with treatment.[22]

Joint and bone angles

Intra-articular AOD9604 with hyaluronic acid performed best for cartilage in the rabbit model.[4]

MOTS-c reduced bone loss in mice after ovariectomy.[23]

Combined and regulated

The dataset found 1 PubMed record for AOD-9604 with MOTS-c, and it is not classed as a study of the pair.

Calculated from pubmed query ("AOD-9604"[tiab] OR AOD9604[tiab]) AND ("MOTS-c"[tiab] OR MOTSc[tiab]); search date 2026-10-02; records returned 1; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key aod-9604__mots-c); no arithmetic applied.

MOTS-c appears among the AMPK activators in WADA's metabolic modulators section.[2]

MOTS-c has no FDA-approved product: the Drugs@FDA lookup returned no match.[24]

Common questions

AOD-9604 vs MOTS-c: which is better for fat loss?

Neither has human fat-loss trials; both results are mouse or rat data, such as the obese-mouse AOD study.[20]

Can AOD-9604 and MOTS-c be used together?

No study has combined them in animals or people according to the search.[21]

Sources

  1. 1FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3Detection and in vitro metabolism of AOD9604.Drug testing and analysis · 2015PMID 25208511Accessed 2 Oct 2026
  4. 4Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.Annals of clinical and laboratory science · 2015PMID 26275694Accessed 2 Oct 2026
  5. 5Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.Hormone research · 2000PMID 11146367Accessed 2 Oct 2026
  6. 6PubMed search: AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab] (22 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.Rapid communications in mass spectrometry : RCM · 2019PMID 30394592Accessed 2 Oct 2026
  8. 8Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization.Medicine and science in sports and exercise · 2025PMID 40674654Accessed 2 Oct 2026
  9. 9Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging · 2022PMID 36490309Accessed 2 Oct 2026
  10. 10Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.Scientific reports · 2021PMID 34413391Accessed 2 Oct 2026
  11. 11PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) (262 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (humans[mh] OR human[tiab] OR participants[tiab] OR patients[tiab] OR volunteers[tiab]) (179 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (randomized controlled trial[pt] OR "clinical trial"[pt] OR "meta-analysis"[pt] OR "systematic review"[pt]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (mice[tiab] OR mouse[tiab] OR rat[tiab] OR rats[tiab]) AND (injection[tiab] OR treatment[tiab] OR administration[tiab] OR treated[tiab]) (72 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16PubMed search: ("AOD-9604"[tiab] OR AOD9604[tiab]) AND ("MOTS-c"[tiab] OR MOTSc[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
  18. 18PubMed search: (AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  19. 19PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab] OR CB4211[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (20 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  20. 20Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity · 2001PMID 11673763Accessed 2 Oct 2026
  21. 21MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction.Journal of molecular medicine (Berlin, Germany) · 2019PMID 30725119Accessed 2 Oct 2026
  22. 22Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration.American journal of physiology. Endocrinology and metabolism · 2024PMID 38170165Accessed 2 Oct 2026
  23. 23Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation.Biochemical and biophysical research communications · 2016PMID 27237975Accessed 2 Oct 2026
  24. 24Drugs@FDA (openFDA) search: active ingredient "MOTS-c"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.